NDA Partners General Manager, Eric Visannounced today that David Wurtman, MD, MBA, a veteran businessman and product development expert, joined the company as an Expert Consultant. dr. Wurtman was previously Chief Executive Officer of Lyric Pharmaceuticals, an ICU therapeutic development company, and Chief Medical Officer of Lucid Diagnostics.
WASHINGTON† June 23, 2022 /PRNewswire-PRWeb/ — NDA Partners General Manager, Eric Visannounced today that David Wurtman, MD, MBA, a veteran businessman and product development expert, joined the company as an Expert Consultant. dr. Wurtman joined the company to support companies with corporate strategy, fundraising, mergers and acquisitions, business development and licensing, product development, market research, product positioning, and clinical regulatory strategy and development. He has particular expertise in assisting emerging and start-up product and platform companies.
dr. Wurtman served as CEO of Lyric Pharmaceuticals, an ICU therapeutic development company he founded, built and successfully funded, and as CMO of Lucid Diagnostics, a medical device company that went public in 2021 via an Initial Public Offering (IPO). He has consulted and led or advised on more than 25 biopharmaceutical, technology platform, medical device, diagnostic and healthcare IT companies on approximately 25 transactions and has raised more than $70 million from Venture Capital, Private Equity, Family Office and the U.S. government. He has deep development expertise in pharmaceuticals, biologics and diagnostic devices and has led successful FDA interactions, including obtaining the FDA Breakthrough Designation.
dr. Wurtman is a Board Certified Internal Medicine physician and in addition to his positions at Lyric and Lucid, he also held positions in Corporate, Business and Product Development at Genzyme, Protein Design Labs, Eos Biotechnology, Kineta and Ansun Biopharma.
According to Dr. Alberto GutierrezManager of the Diagnostic Device Practice of NDA Partners, “Dr. Wurtman brings valuable experience in business development, product development and helps establish and lead development teams for early stage drug, biological and diagnostic device companies. Partners.”
dr. David Wurtman received his medical degree from Harvard Medical School and MBA from MIT Sloan School of Management† He completed his residency in internal medicine at Mount Auburn, a Harvard Teaching Hospital, and associations with Ben Gurion University of the Negev† Israel and the Department of Hormone Research, Weizmann Institute, Israel†
About NDA Partners
NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology and medical device industries worldwide. Highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former senior executives from the pharmaceutical industry and regulatory authorities; and a comprehensive list of highly skilled experts in specialized fields, including non-clinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submission, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.
Eric VisGeneral manager
Eric VisNDA Partners, 540-738-2550, FishEric@ndapartners.com
SOURCE NDA partners